William Blair research analyst Myles Minter comments on an Alzheimer’s drug in development by pharmaceutical company Biogen in this Washington Post article.
In this story on the results of a Biogen-led clinical trial about the drug, Minter told the publication that the trial results were “near best-case scenario given the limitations” of the type of drug in development.